How to Lower Cholesterol: Statins, Diet and Everything Else, Ranked by What the Studies Found

In plain words: High cholesterol goes with heart disease, newer drugs cut LDL a lot, and the dramatic statin and risk figures shrink in careful studies. 1. Risks. High LDL or total cholesterol is linked with cardiovascular disease (ratio 1.58 (95% CI 1.26 to 1.98), prediction interval 0.53 to 4.72, k = 25), hypertension and other cardiometabolic conditions (1.58 (95% CI 1.37 to 1.81)) and kidney disease (1.36 (95% CI 1.16 to 1.59)), all three Firm; coronary disease, stroke, liver disease and cancer are Provisional; death (1.05 (95% CI 0.91 to 1.20)), diabetes and dementia are not supported. 2. What small studies exaggerate. For high cholesterol the ratio rises by a factor of 4.0 (95% CI 1.5 to 10.5) per unit of standard error; the least precise third of studies pools to 1.80 against 1.19 for the most precise third, robust to clustering and to omitting any family. Adjustment (1.12), publication from 2021 (1.22), East Asia (0.88) and ratio type (1.28) do not explain ratios within family (null). 3. Lowering LDL. PCSK9 inhibitors and inclisiran lower LDL by a median of 50% in reported falls (k = 42); diets and supplements by about 10 mg/dL (0.25 mmol/L) in meta-analyses, where the less precise half is 3.3 times larger than the more precise half (-10.1 against -3.1 mg/dL). Statin LDL falls are too thin (k = 3) to rank. 4. Statin benefit, two kinds of evidence. Cohorts give 0.70 (95% CI 0.63 to 0.77) for all-cause mortality (k = 22, Firm) against a reader-confirmed meta-analysis median of 0.86 (k = 5); the gap fits confounding by indication and healthy-user bias, not a larger drug effect. 5. Side-effect claims. New-onset diabetes 1.50 (95% CI 1.22 to 1.84) (Provisional, failing the precise-half test; blinded-trial odds ratio about 1.09) and muscle symptoms 1.49 (95% CI 1.00 to 2.23) (not supported); harms are small where the evidence is best and larger in cohorts that mention them. 6. News against search. Validated news openings on statin side effects fell from 4.3% to 0.8% (change -3.4 points, 95% CI -4.2 to -2.7) while searches for statin side effects reached 1.97 times their 2019 level (weather control 1.13); detrended, deseasonalised news and search correlate at 0.21 for cholesterol and are not stable over time. 7. Context. The research layer holds 22,795 core studies (2017 to 2025), of which 9% have drug treatment as their focus; the search index for cholesterol averaged 78 in 2025 to 2026; 12,044 news openings were read. 8. Method. Ratio rows were re-read from quotations by a strict parser (280 of 3,368 candidates removed) and pooled within outcome family (DerSimonian-Laird, prediction intervals); every field and flag used passed a blind second reading at 70% agreement or better; failed fields (therapy estimates, per cent LDL falls, age) were restricted to confirmed rows or dropped. Research preprint, not peer reviewed. The ratios are associations reported in the cited studies and are not medical advice. Author: Narendra Kumar (ORCID 0009-0001-7468-6100). This paper was not produced entirely by AI; the blind second readers used for validation are AI readers, named in the paper.